Innate Pharma (CHIX:IPHP) Short Ratio


CHIX:IPHP Innate Pharma SA CHIX:IPHP
34 GF Score
Price €1.43
GF Value €0.12
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:IPHP
34GF Score
Innate Pharma SA CHIX:IPHP
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innate Pharma (CHIX:IPHP) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of €1.43 is trading 1088.3% above its estimated GF Value™ of €0.12.

Key valuation signals for CHIX:IPHP:

  • Short Ratio:
  • GF Value™: €0.12 vs. price of €1.43 (1088.3% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IPHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
34GF Score

Get the complete analysis for CHIX:IPHP

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.43
Price
€0.12
GF Value